Introduction This study aims to assess the cost effectiveness of romosozumab versus teriparatide, both sequenced to denosumab, for the treatment of severe postmenopausal osteoporosis at very high risk
aQALYs: Quality Adjusted Life YearsbICUR: Incremental Cost-Utility RatiocICER: Incremental Cost-Effectiveness RatioCost-effectiveness: base case results.
IntroductionThis study aims to assess the cost effectiveness of romosozumab versus teriparatide, both sequenced to denosumab, for the treatment of severe postmenopausal osteoporosis at very high risk